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I n 2001, Van den Berghe et al. (1)reported that intensive insulintherapy in a surgical intensivecare unit (ICU) population re-
duces mortality and morbidity rates.
The occurrence of hypoglycemia was
increased in the intensive treatment group:
5.1% of patients experienced a glucose value
40 mg/dL at least once vs. 0.8% in the
control group (1). In our ICU, we found hy-
poglycemia rates comparable to the conven-
tional group before publication of the Van
den Berghe study, and after publication we
found hypoglycemia rates comparable to the
intensive treatment group (2). Little is known
about the pathophysiology and consequences
of hypoglycemia in the ICU, in contrast with
an extensive body of literature on pathophys-
iology and consequences of hypoglycemia in
diabetes mellitus (3). However, the (per-
ceived) risk of hypoglycemia may impair im-
plementation of intensive insulin therapy in
intensive care units.
To develop preventive measures for
hypoglycemia, we examined the associa-
tion of candidate circumstances with hy-
poglycemia in the ICU.
METHODS
Patient Cohort
All 2,272 patients who were admitted to
our ICU between September 1, 2002, and Sep-
tember 1, 2004, were identified.
Defining the Hypoglycemia
Cases
All occurrences of hypoglycemia (defined
as a glucose value 45 mg/dL) between Sep-
tember 1, 2002, and September 1, 2004, were
collected from the patient data management
system (Metavision, iMDsoft, Sassenheim, the
Netherlands). Hypoglycemic values within 1
hr of the index episode in the same patient
were considered to be repeated measurements
and were disregarded. All patients were included
in the analysis with the first hypoglycemic event
only; subsequent events were not analyzed.
Defining the Controls
The aim of this study was to examine
whether certain circumstances predispose pa-
tients to develop hypoglycemia during ICU
admission. Therefore, circumstances of a case
were compared with circumstances of a con-
trol at the same point in time (nested case-
control method), which leads to complete ad-
justment for the effect of duration and its
determinants. The control patients were ran-
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Objective: The introduction of strict glycemic control in the
intensive care unit has increased the risk for hypoglycemia. In
this study we examined the association between predefined cir-
cumstances and the occurrence of hypoglycemia in the intensive
care unit.
Design: Retrospective cohort study.
Setting: Academic medical center.
Patients: All episodes of hypoglycemia (glucose value <45
mg/dL) in our intensive care unit between September 2002 and
September 2004 were identified. Presence of predefined circum-
stances previously associated with hypoglycemia was scored
around the moment of hypoglycemia using a patient data man-
agement system and in-hospital charts. Patients with a first
hypoglycemic event were contrasted to controls from the same
cohort, who were matched for time since admission, to correct for
the effect of length of stay. Data were analyzed using conditional
logistic regression analysis.
Interventions: None.
Measurements and Main Results: Of 2,272 patients, 156 (6.9%)
experienced at least one episode of hypoglycemia. Continuous
venovenous hemofiltration with bicarbonate-based substitution
fluid (odds ratio [OR], 14; 95% confidence interval [CI], 1.8–106),
a decrease of nutrition without adjustment for insulin infusion
(OR, 6.6; 95% CI, 1.9–23), diabetes mellitus (OR, 2.6; 95% CI,
1.5–4.7), insulin use (OR, 5.3; 95% CI, 2.8–11), sepsis (OR, 2.2;
95% CI, 1.2–4.1), and inotropic support (OR, 1.8; 95% CI, 1.1–2.9)
were associated with hypoglycemia. Simultaneous octreotide and
insulin use (OR, 6.0; 95% CI, 0.72–50) may also be associated with
hypoglycemia. Gastric residual during enteral nutrition without
adjusting insulin infusion, liver failure, continuous venovenous
hemofiltration with lactate-based substitution fluid, diminished
glomerular filtration rate, dose diminishment of glucocorticoids or
catecholamines, and use of -blocking agents were not associ-
ated with hypoglycemia. Adjusting for age, gender, and Acute
Physiology and Chronic Health Evaluation II score at admission
did not materially change ORs.
Conclusion: Use of bicarbonate-based substitution fluid during
continuous venovenous hemofiltration, a decrease of nutrition
without adjustment for insulin infusion, a prior diagnosis of dia-
betes mellitus, sepsis, and need for inotropic support were found
to be associated with hypoglycemia. Simultaneous use of insulin
and octreotide may be associated with hypoglycemia. (Crit Care
Med 2006; 34:96–101)
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domly selected from the “at-risk” population
between September 1, 2002, and September 1,
2004. The at-risk population (risk set) com-
prised all patients at the time of the event in a
case who had a stay in the ICU of at least the
same duration as the cases and had not had a
hypoglycemic event (glucose value 45 mg/
dL) until the first hypoglycemic episode in the
case. This sampling method may also be seen
as matching on time, which needs to be taken
into account given the variable durations of
stay in the ICU. A patient could serve as a
control only once. However, the nested-case-
control method implies that a patient may be
included both in the case and in the control
group. The circumstances before and during
hypoglycemia were scored in the case group
and before and during the matched moment
in the control group (index moment, Fig. 1).
Setting
Our ICU is a 28-bed “closed-format” de-
partment of a university teaching hospital, in
which medical and surgical patients (includ-
ing cardiothoracic and neurosurgical patients)
are under the direct care of the ICU team. The
ICU team comprises eight full-time intensiv-
ists, eight subspecialty fellows, and 12 resi-
dents. All beds are equipped with a patient data
management system. Strict glycemic control,
with target glucose levels between 81 and 144
mg/dL, was aimed for after the publication of
the Van den Berghe study. A higher target
range than 80–110 mg/dL, which was used in
the Van den Berghe study (1), was chosen
because of concern of the ICU staff for hypo-
glycemia in a “real-life,” nonstudy setting. A
glucose level at which insulin treatment
should be started was left to the discretion of
the attending physician. Insulin infusion was
increased by 1 IU/hr in case of blood glucose
144 mg/dL, and an additional bolus of 8 IU of
insulin was administered in case of blood glu-
cose 288 mg/dL. In case of blood glucose
80 mg/dL, insulin infusion was stopped. In-
sulin was administered through continuous
intravenous infusion (Actrapid®, Novo Nor-
disk Farma, Alphen aan de Rijn, the Nether-
lands) and was nurse-driven. Implementation
of this protocol led to a decrease in mean
blood glucose from 162 mg/dL (SD 58, before
implementation, in 2000) to 133 mg/dL (SD 
45, after implementation, in 2003) (2). There
was no standard protocol for treatment of hy-
poglycemia or for the frequency of glucose
measurements after hypoglycemia. Whole
blood glucose was measured with an on-site
arterial blood gas analyzer (Ciba Corning 865,
Chiron Diagnostics, Medford, MA). Creatinine
was routinely measured every morning; other
laboratory variables, such as bilirubin, were
measured only when clinically indicated.
Candidate Risk Factors for
Hypoglycemia
We predefined a number of factors we con-
sidered to be associated with hypoglycemia,
based on literature review and clinical reason-
ing. These included a) discontinuation or low-
ering of nutrition or glucose containing fluids
without adjusting insulin administration (1);
b) gastric residual during enteral nutrition
without adjusting insulin administration; c)
presence of conditions previously described to
predispose for hypoglycemia (4, 5), including
diagnosis of diabetes mellitus before ICU ad-
mission, sepsis, hemodynamic shock, liver
failure, renal failure, or renal replacement
therapy; and d) medication use previously de-
scribed to be associated with hypoglycemia (6,
7) and discontinuation or dose diminishment
of drugs associated with hyperglycemia.
Nutrition and Glucose-
Containing Fluid Administration
As a rule, patients admitted to our ICU
receive intravenous glucose 5% at a rate of 30
mL/hr, and enteral or parenteral feeding is
initiated within 24 hrs of ICU admittance. Gas-
tric residual during enteral nutrition was de-
fined as residual 50% of the hourly enteral
feeding dose within 6 hrs before the index
moment. Changes in nutrition or administra-
tion of glucose-containing solutions within 6
hrs before the index moment were scored.
Changes in insulin administration were scored
within 3 hrs before the index moment, and
insulin dosage was scored immediately before
the index moment.
Predisposing Conditions
Prior diagnosis of diabetes mellitus and
insulin use before ICU admittance was retro-
spectively scored by reviewing in-hospital
charts. Sepsis was defined as systemic inflam-
matory response syndrome at the index mo-
ment and a culture-proven infection within 48
hrs before or after the index moment (8). For
patients with hypoglycemia, heart rate during
the last glucose value 80 mg/dL before the
moment of hypoglycemia was retrieved, to
avoid using tachycardia as a result of hypogly-
cemia for classification of systemic inflamma-
tory response syndrome. Hemodynamic status
was scored at the index moment according to
Sepsis-related Organ Failure Assessment
(SOFA) classification for hemodynamic status
(9). Liver failure was scored according to
SOFA classification (9) for liver failure using
the plasma bilirubin concentration in the last
24 hrs before the index moment. Creatinine
level 24 hrs before the index moment and
estimated body weight at ICU admittance were
used to calculate creatinine clearance with the
Cockcroft-Gault formula (10). Patients with
acute renal failure were treated with continu-
ous venovenous hemofiltration (CVVH; Di-
apact, B-Braun, Melsungen, Germany). Either
bicarbonate-based or lactate-based substitu-
tion fluid (SH-53/SH-19, B-Braun, Melsungen,
Germany) was used as predilution fluid. Sub-
stitution fluid was generally infused at a rate
of 2000 mL/hr with a blood flow of 150 mL/
min. In our institution, lactate-based substi-
tution fluid is the first choice; septic patients
and patients with cardiac failure are treated
with bicarbonate-based substitution fluid.
Medication Use
Drug use previously associated with hypo-
glycemia (insulin, oral antidiabetic drugs,
Figure 1. Matching of cases. Arrows indicate index moment; h indicates a hypoglycemic episode.
Controls were drawn from the at-risk population. This means that controls had to be admitted at least
as long as the case was admitted until the first episode of hypoglycemia (h) and that controls did not
have a hypoglycemic episode before the hypoglycemic episode in the case. Thus, control A could not
have served as a control for case B. Circumstances were scored around the moment of hypoglycemia
in the case and around the time-matched moment in the control (referred to as “index moment”).
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-blocking agents, quinine or quinine deriva-
tives, simultaneous octreotide and insulin
treatment, pentamidine, disopyramide, aspi-
rin, trimethoprim sulfamethoxazole) (6, 7)
and drugs associated with hyperglycemia (glu-
cocorticoids, catecholamines) were scored ei-
ther when they were discontinued or the dose
was diminished. We scored insulin and cate-
cholamine use within 3 hrs before the index
moment, long-acting sulfonylurea drugs
within 96 hrs before the index moment, and
all other medication within 24 hrs before the
index moment.
Statistical Analysis
Conditional logistic regression analysis
was used to calculate odds ratio (OR) and 95%
confidence interval (CI), using SPSS version
11.5.1 (SPSS, Chicago, IL). This analysis takes
the stratified sampling of the matching into
account and resembles an analysis stratified
for each paired case and control. This implies
that all analyses, including the univariate
analysis, are adjusted for duration of admis-
sion. All factors were entered as dichotomous
variables except for creatinine clearance,
which was entered as a continuous variable.
All predefined putative risk factors were ana-
lyzed with univariate regression analysis and
with multivariate regression analysis correct-
ing for age, gender, and Acute Physiology and
Chronic Health Evaluation (APACHE) II score
at admission and for number of glucose mea-
surements before the index moment in an
additional analysis. All odds ratios are pre-
sented with 95% confidence intervals, which
were derived from the likelihood functions of
the models.
The Ethical Review Board of the Academic
Medical Center waived the need for informed
consent because of the retrospective nature of
the study.
RESULTS
Between September 1, 2002, and Sep-
tember 1, 2004, 2,503 ICU admissions of
2,272 different patients were identified,
comprising 32.1 patient-years. Almost
half of all admitted patients were cardio-
surgical patients. The median duration of
stay was 1.8 days. Mortality rate in our
ICU during this period was 12.3% (Table
1).
We found 245 hypoglycemic events in
156 patients, indicating that 6.9% of pa-
tients experienced at least one hypogly-
cemic episode during one or more ICU
admittance. The incidence of hypoglyce-
mia was 245 of 32.1 (7.6) per patient-
year. Fifty-two patients (33%) experi-
enced more than one hypoglycemic event
(31 patients two events, 12 patients three
events, five patients four events, three
patients five events, and one patient eight
events). The first hypoglycemic event oc-
curred after 1.7 days of ICU admittance
(range 0–60 days). Our matching strat-
egy, drawing patients from the “risk set,”
implied that the pool of control patients
became smaller with increasing time to
the first hypoglycemic event. Moreover,
for one patient, no adequate control
could be identified because hypoglycemia
occurred too long after admission to be
matched with a control.
Baseline characteristics of patients
with and without hypoglycemia are listed
in Table 1 (data were 99% complete).
More patients with hypoglycemia were
female compared with controls (OR, 1.7;
95% CI, 1.1–2.7).
The number of glucose measurements
until the index moment was similar in
the case and the control group (median
13 [interquartile range 5–42] in patients
with hypoglycemia vs. median 17 [inter-
quartile range 6–50] in controls). The
first blood glucose after hypoglycemia
was determined after a median of 74 mins
(range 8–450 mins). Within 1 hr after
hypoglycemia, 60 of 156 (38%) patients
had a glucose value measured, 42 of
whom (70%) had a glucose value 80
mg/dL. Within 3 hrs after hypoglycemia,
143 of 156 (92%) patients had a glucose
value measured, 135 of whom (94%) had
a glucose 80 mg/dL.
Nutrition and Glucose-
Containing Fluid Administration
Forty-four percent of the cases vs.
42% of the controls did not receive any
nutrition at the index moment. Patients
generally received continuous enteral nu-
trition only (43% of the cases vs. 44% of
the controls). The remainder received
parenteral nutrition (4.5% of cases vs.
7.7% of controls), oral nutrition (3.2% of
cases vs. 4.5% of controls), or a combi-
nation of enteral with oral or parenteral
nutrition (4.5% of cases vs. 0.6% of con-
trols). Lowering or discontinuing nutri-
tion (enteral, parenteral, or oral) without
adjusting insulin infusion was associated
with hypoglycemia (OR, 6.6; 95% CI,
1.9–23). Lowering glucose 5% solution
without adjusting insulin infusion
seemed associated with hypoglycemia
(OR, 6.0; 95% CI, 0.72–49), although it
was not statistically significant. The fre-
quency of gastric residual in patients with
enteral feeding without adaptation of in-
sulin infusion did not differ in both co-
horts (OR, 1.0; 95% CI, 0.43–2.3).
Predisposing Conditions
Diabetes Mellitus. Patients with hypo-
glycemia had more often been diagnosed
with diabetes mellitus (OR, 2.6; 95% CI,
1.5–4.7) and used insulin before ICU ad-
mittance more frequently (OR, 17; 95%
CI, 2.3–127) than control patients. Pa-
tients with a prior diagnosis of diabetes
mellitus were also more likely to experi-
ence more than one hypoglycemic event
(OR, 2.3; 95% CI, 1.1–4.7). At the time of
hypoglycemia, patients with diabetes re-
ceived a similar dose of insulin compared








Male gender, n (%) 1412 (62) 81 (52) 103 (66)
Age, yrs, mean (SD) 60.3 (16.4) 60.8 (16.2) 60.9 (16.5)
SAPS score at admission, median (IQR) 36 (27–47) 47 (37–59) 42 (31–55)
APACHE II score at admission, median (IQR) 16 (12–21) 20 (16–26) 18 (14–24)
ICU mortality, n (%) 279 (12) 42 (27) 32 (20)
ICU length of stay, days, median (range) 1.8 (0.004–103) 6.8 (0.01–103) 5.1 (0.5–68)
Referring specialty, n (%)
Internal medicine 268 (12) 41 (26) 25 (16)
Cardiology/pulmonology 194 (8.5) 21 (14) 18 (12)
Neurology/neurosurgery 282 (13) 12 (7.7) 19 (12)
General surgery 451 (20) 37 (24) 41 (26)
Thoracic surgery 1058 (47) 51 (25) 39 (33)
Obstetrics/gynecology 18 (0.8) 1 (0.6) 1 (0.6)
Glucose value at index moment, mg/dL, median (IQR) — 37 (31–41) 124 (108–146)
Mechanical ventilation at index moment — 114 (74) 108 (71)
SAPS, Simplified Acute Physiology Score; IQR, interquartile range; APACHE, Acute Physiology and
Chronic Health Evaluation; ICU, intensive care unit.
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with patients without a prior diagnosis of
diabetes (3.9 IU/hr, range 0.5–20.5 for
cases vs. 3.6 IU/hr, range 1.0–12 for con-
trols).
Sepsis. Hypoglycemia occurred more
often in patients with sepsis than in pa-
tients without sepsis (OR, 2.2; 95% CI,
1.2–4.1).
Liver Failure. A SOFA score for liver
failure of 1 was not associated with
hypoglycemia (OR, 0.33; 95% CI, 0.04–
3.2 and OR, 1.7; 95% CI, 0.85–3.3 when
considering all patients with missing bil-
irubin data [60%] as having no liver
failure).
Hemodynamic Status. Having a SOFA
score of 1 for shock was associated with
an increased risk for hypoglycemia (OR,
1.8; 95% CI, 1.1–2.9).
Renal Function and Renal Replace-
ment Therapy. Patients with hypoglyce-
mia had a similar creatinine clearance
rates compared with controls (Fig. 2).
Patients with hypoglycemia were more
often treated with CVVH compared with
controls (26 of 153 vs. eight of 155; OR,
3.7; 95% CI, 1.6–8.6). In subanalysis, the
increased risk was only found in patients
receiving bicarbonate substitution fluid
(OR, 14.0; 95% CI, 1.8–106). Patients re-
ceiving lactate-based substitution fluid
were not at higher risk for hypoglycemia
(OR, 1.4; 95% CI, 0.5–3.8).
Medication
The association between occurrence of
hypoglycemia and use of drugs previously
associated with hypoglycemia or hyper-
glycemia is summarized in Figure 2. As
expected, insulin use was associated with
hypoglycemia (OR, 5.4; 95% CI, 2.8–10).
Octreotide use was found in six cases
(3.8%) compared with one control (0.6%;
OR, 6.0; 95% CI, 0.72–49). In all cases of
octreotide use, insulin was administered
concomitantly via continuous intrave-
nous infusion. None of the patients re-
ceived pentamidine or disopyramide.
Figure 2 provides ORs and 95% CI of
predefined risk factors adjusted for age,
gender, and APACHE II score at admis-
sion. Additional analysis showed that also
adjusting for number of glucose values
measured before the index moment did
not materially change ORs (data not
shown).
DISCUSSION
In this study we examined predefined
candidate circumstances associated with
occurrence of hypoglycemia in ICU pa-
tients. We found that glucose values 45
mg/dL are common in our ICU and oc-
curred at least once in almost 7% of all
patients. This is similar to the results of
Van den Berghe et al. (1), who found that
5.1% of patients who received strict glu-
cose control experienced at least one glu-
cose value 40 mg/dL. Furthermore, we
Figure 2. Results of conditional regression analysis. *All odds ratios except the odds ratio for female gender were adjusted for age, gender, and Acute
Physiology and Chronic Health II score at admission. Error bars indicate 95% confidence intervals. SOFA, Sepsis-related Organ Failure Assessment; CVVH,
continuous venovenous hemofiltration.
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found that treatment with CVVH, partic-
ularly when bicarbonate-based substitu-
tion fluid was used, discontinuing nutri-
tion without adjusting insulin therapy, a
prior diagnosis of diabetes mellitus, insu-
lin treatment, sepsis, and need for inotro-
pic or vasopressor drugs were associated
with hypoglycemia in the ICU, indepen-
dent of age, gender, and APACHE II score
at admission.
It is difficult to define causal factors
for hypoglycemia in the ICU. Many
known and unknown, interrelated factors
may play a role in the development of
hypoglycemia in the ICU that cannot be
corrected for in multivariate analysis.
However, by matching the hypoglycemia
cases to control patients with the same
ICU exposure (nested case-control
method), the reported ORs are indepen-
dent of time spent in the ICU and of
factors that are closely related to length
of ICU stay, including, for instance, the
number of glucose measurements before
hypoglycemia. Furthermore, in multivar-
iate analysis we also corrected ORs and
95% CIs for the most important possible
confounders (age, gender, and APACHE II
score at admission). A second limitation
is that more patients than expected had
hypoglycemia without reported insulin
therapy (n  30, 19%). Data on drug use
before ICU admittance, such as insulin
use, were limited. We searched for insulin
use before ICU admittance for all patients
who experienced hypoglycemia within 6
hrs after admittance without reported in-
sulin use (n  16; 10%), but we could
only confirm insulin use in two of these
patients. A third limitation of our study is
that the investigators were aware of the
patient being a case or a control at the
time of data collection, which may have
led to a bias in the data collection.
More than 40% of patients did not
receive any means of nutrition, even
though the policy in our ICU is to start
nutrition in all patients within 24 hrs
after admission. The fact that all patients
who were admitted to the ICU were eligi-
ble for the study, including patients who
were admitted for 24 hrs, may explain
the relatively high percentage of patients
who received no means of nutrition at the
index moment. Lowering or discontinu-
ing nutrition without adjusting insulin
therapy was associated with hypoglyce-
mia but did not occur as frequently as we
expected (only in 11% of all hypoglyce-
mia cases), whereas Van den Berghe (11)
reported this as the most frequent cause
of hypoglycemia in her study. Awareness
and education may prevent these unin-
tended errors. In ICUs equipped with a
patient data management system, a
pop-up message to warn the attending
nurse to adjust insulin administration as
soon as nutrition is lowered or discontin-
ued may be a simple method to lower the
incidence of hypoglycemia.
Patients with a diagnosis of diabetes
mellitus before ICU admission were more
likely to experience (recurrent) hypogly-
cemia. Patients with a prior diagnosis of
diabetes did not receive more insulin at
the time of hypoglycemia compared with
patients without known diabetes. Pa-
tients with type 1 diabetes and patients
with longstanding type 2 diabetes may
have an impaired counterregulatory re-
sponse (3). This may help to explain why
patients with insulin use before ICU ad-
mittance were at a higher risk to develop
hypoglycemia.
Patients treated with CVVH were al-
most four times more likely to experience
hypoglycemia. It may be hypothesized
that in patients treated with CVVH, insu-
lin action is prolonged because insulin
clearance is impaired. However, in CVVH
with hemodialysis, no difference was
found between insulin concentrations be-
fore and after the hemofiltration dialysis
filter (12), and in our study, creatinine
clearance was hardly different in patients
with and without hypoglycemia. Theoret-
ically, CVVH may ameliorate insulin sen-
sitivity through increased clearance of in-
flammatory molecules, such as tumor
necrosis factor- and interleukins, anal-
ogous to the controversial hypothesis
that CVVH is beneficial for patients with
sepsis (13).
Interestingly, patients who received
bicarbonate-based substitution fluid were
at higher risk for hypoglycemia, in con-
trast to patients who received lactate-
based substitution fluid. The bicarbonate-
based substitution fluid used in our
institution contains less glucose (100 mg/
dL) than the lactate-based substitution
fluid (260 mg/dL). However, because of
predilution with substitution fluid and
the equimolar filtration of glucose, no
major glucose loss in the ultrafitrate can
be expected. Indeed, in our study blood
glucose levels were similar before hypo-
glycemia in patients with and without
CVVH and in patients with bicarbonate-
based and lactate-based substitution ther-
apy (data not shown). A recent study sug-
gests that during hemodialysis,
erythrocyte glucose consumption is in-
creased, caused by high concentrations of
bicarbonate in the dialysate fluid. High
bicarbonate concentrations would initi-
ate changes in cytoplasmic pH, which in
turn would increase anaerobic glycolysis
in erythrocytes (14). Moreover, lactate
can serve as a substrate for gluconeogen-
esis whereas bicarbonate cannot. The
most likely explanation, however, is that
the sickest patients receive bicarbonate-
based substitution fluid rather than lac-
tate-based substitution fluid in our hos-
pital and that the sickest patients are at
increased risk for hypoglycemia.
Simultaneous insulin and octreotide
use tended to be associated with hypogly-
cemia, although this was not statistically
significant, probably because of low prev-
alence. There is, however, pathophysio-
logic evidence that simultaneous oct-
reotide and continuous intravenous
insulin administration may predispose
patients to hypoglycemia. Octreotide is a
long-acting somatostatine analogue that
is usually prescribed in ICU in patients
after abdominal surgery because of its
vasoconstrictive effect on the splanchnic
circulation (15). However, octreotide also
has profound endocrine effects, as it in-
hibits the secretion of growth hormone,
insulin, and glucagon. Exogenous insulin
infusion suppresses endogenous insulin
production, thereby abolishing the de-
crease of endogenous insulin production
as a first defense against hypoglycemia.
Counterregulation is further impaired by
inhibitory effects of octreotide on gluca-
gon secretion and, to a lesser extent, its
inhibitory effects on growth hormone se-
cretion. Simultaneous use of insulin and
octreotide may therefore predispose pa-
tients to hypoglycemia.
An additional finding of our study was
that more patients with hypoglycemia
were female compared with patients
without hypoglycemia. Women may have
a lower counterregulatory threshold for
hypoglycemia then men (16). Female
gender was also found to be associated
with an increased occurrence of hypogly-
cemia in elderly hospitalized patients (4).
Because some clinics have separate
medical and surgical ICUs, and because
hypoglycemia rates and possible predis-
posing factors for hypoglycemia may be
different in surgical vs. medical ICUs, it
would be interesting to examine whether
the same associations can be found in
surgical and nonsurgical patients. Al-
though this study was not designed for
such a subanalysis, we did perform a sep-
arate analysis for surgical and nonsurgi-
cal patients. As can be expected with a
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50% loss of power, 95% CIs increased and
some of the observed relationships lost
their significance. Nevertheless, general
tendencies were similar overall.
It can be concluded from the large
mortality reduction with strict glycemic
control observed in the Van den Berghe
study that the beneficial effects of lower-
ing hyperglycemia outweigh possible det-
rimental effects of hypoglycemia. How-
ever, the (perceived) risk of hypoglycemia
is likely to impair full implementation of
intensive insulin therapy. Hypoglycemia
should therefore be avoided, but not at
the cost of worsening glycemic control.
Awareness of possible risk factors and
more frequent glycemic control may
lower the occurrence of hypoglycemia in
patients who are at increased risk for
hypoglycemia.
CONCLUSIONS
In this study, we found that CVVH
treatment with bicarbonate substitution
fluid, discontinuation of nutrition with-
out adjustment of insulin therapy, a prior
diagnosis of diabetes mellitus, insulin
treatment, sepsis, and need for inotropic
or vasopressor drugs were associated with
occurrence of hypoglycemia in our ICU.
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